Palatin Technologies (PTN) Net Shares Issued and Repurchased (2013 - 2025)
Palatin Technologies' (PTN) quarterly Net Shares Issued and Repurchased came in at $48000.0 in Q4 2025, up 805.83% quarter-over-quarter from $5299.0 in Q2 2024.
Analysis
Palatin Technologies (PTN) Net Shares Issued and Repurchased (2013 - 2025) Analysis & Trends
Palatin Technologies (PTN) has reported Net Shares Issued and Repurchased for 13 consecutive years, with $48000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Shares Issued and Repurchased changed N/A year-over-year to $48000.0; the trailing twelve-month figure through Dec 2025 stood at $48000.0 (changed N/A YoY), and the FY2024 full-year result was $5299.0, down 99.26% from the prior year.
- Net Shares Issued and Repurchased climbed to $48000.0 in Q4 2025 per PTN's latest filing, from $5299.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $141844.0 in Q2 2021 and bottomed at $1211.0 in Q2 2022.
- Historically, Net Shares Issued and Repurchased has averaged $48048.4 across 5 years, with a median of $17056.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Net Shares Issued and Repurchased sank 99.15% in 2022, then surged 294.47% in 2023.
- Over 5 years, Net Shares Issued and Repurchased stood at $118152.0 in 2021, then sank by 85.56% to $17056.0 in 2022, then slumped by 71.99% to $4777.0 in 2023, then advanced by 10.93% to $5299.0 in 2024, then surged by 805.83% to $48000.0 in 2025.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $48000.0, $5299.0, and $4777.0 for Q4 2025, Q2 2024, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 48,000.00 |
| Jun 30, 2024 | 5,299.00 |
| Jun 30, 2023 | 4,777.00 |
| Sep 30, 2022 | 17,056.00 |
| Jun 30, 2022 | 1,211.00 |
| Sep 30, 2021 | 118,152.00 |
| Jun 30, 2021 | 141,844.00 |
| Sep 30, 2020 | 154,500.00 |
| Jun 30, 2020 | 5.78 Mn |
| Sep 30, 2019 | 77,100.00 |
| Jun 30, 2019 | 2.34 Mn |
| Sep 30, 2018 | 133,851.00 |
| Jun 30, 2018 | 4.18 Mn |
| Jun 30, 2017 | 4.12 Mn |
| Jun 30, 2016 | 355,000.00 |
| Jun 30, 2015 | 975,800.00 |
| Jun 30, 2014 | 603,400.00 |
| Jun 30, 2013 | 1.81 Mn |